Business
CytoSorbents Announces the "CytoSorb Therapy in COVID-19 ICU Patients" (CTC) Registry Is Actively Enrolling
MONMOUTH JUNCTION, N.J., Sept. 8, 2020 /PRNewswire/ -- CytoSorbents Corporation (Nasdaq: CTSO), a critical care immunotherapy leader commercializing its
About this update from Cytosorbents Corporation
[{"type":"text","content":"MONMOUTH JUNCTION, N.J., Sept. 8, 2020 /PRNewswire/ -- CytoSorbents Corporation (Nasdaq: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, announced today that the U.S.-based \"CytoSorb Therapy in COVID-19 ICU Patients,\" (\"CTC\") Registry, is now live and actively enrolling patients. Multiple U.S. centers are taking part in the registry, with the first patient already successfully included by the University of Chicago Medicine. The CTC registry has been designed to uniformly capture high quality, anonymized clinical outcomes data on adult, critically-ill, COVID-19 patients treated with CytoSorb under FDA Emergency Use Authorization (EUA) granted in April 2020. These data may result in one or more publications that highlight best practices on how to best treat cytokine storm in these patients with CytoSorb. \n\n \n \n \n \n \n \n\n \nDr. Tae H. Song, Director of the Acute Mechanical Circulatory Support and Extracorporeal Membrane Oxygenation (MCS/ECMO) program, and Surgical Director of the Lung Transplant Program at the University of Chicago stated, \"The COVID-19 pandemic has had a profound impact on the use of ECMO at the University of Chicago Medicine, and at other institutions. We have been confronted with critically-ill COVID-19 patients suffering rapid decline in pulmonary function requiring ECMO support, with a limited number of proven treatment options. The CytoSorb device can be integrated into ECMO circuits to remove the inflammatory cytokines that can cause a \"cytokine storm\" and many harmful effects to the patient. The Food and Drug Administration issued an Emergency Use Authorization, allowing us to utilize this therapy for COVID-19 patients with severe disease. In these patients, we have seen potential benefits of the device, enabling us to wean patients from ECMO and mechanical ventilation. Now with the advent of the CytoSorb Therapy In COVID-19 (CTC) Registry, institutions around the country will be collecting de-identified clinical data from these patients, to better understand how CytoSorb therapy may be of benefit in COVID-19. We are happy to be the first center to provide data to the CTC Registry to achieve this important goal.\"\nDr. Efthymi...